News

While Ozempic (semaglutide) doesn’t cause heart problems per se, research has found a link between the use of Ozempic and some heart issues that could give patients a cause for concern. This new research had made some people interested in semaglutide medications cautious about taking GLP-1 drugs given the potential health risks. Yet Ozempic, Wegovy, Zepbound, and similar medications continue to ...

Ozempic (semaglutide) doesn’t directly cause headaches in patients, but the GLP-1 medication can contribute to a headache given how the drug affects the body. In fact, popular type 2 diabetes and weight loss drugs like Ozempic have been linked to a number of mild to severe health issues. It’s the reason some patients have been cautious about taking Ozempic even though GLP-1 medications continu...

On April 30, 2025, Bursor & Fisher, P.A. announced that it will be opening its fourth office in White Plains, New York later this year.  Bursor & Fisher Partner, Philip L. Fraietta, will become Managing Partner of the new office.  The firm is excited to continue its growth, while maintaining its standard of excellence....

On April 9, 2025, the Honorable Algenon L. Marbley, United States District Court Judge for the Southern District of Ohio, issued an unsealed Opinion & Order granting Plaintiff's motion for class certification in Kirkbride v. The Kroger Co., 2:21-cv-00022-ALM-EPD (S.D. Ohio).  Plaintiffs allege that Defendant The Kroger Company overcharged insured consumers for generic prescription medicatio...

On March 19, 2025, the Honorable Kenneth M. Karas of the Southern District of New York issued an Opinion and Order granting Plaintiff's motion for class certification in Newman v. Bayer Corporation, Case No. 7:22-cv-07087 (S.D.N.Y.).  Plaintiff alleges Bayer misrepresented the serving size of its "One A Day" gummy vitamins, such that consumers paid twice as much for the product despite receivin...

On April 22, 2025, the Honorable Lizette Colon of the Supreme Court of New York, County of Richmond issued an Order granting Plaintiff's motion for class certification in the case captioned Cammayo v. 1and8, Inc. d/b/a Museum of Ice Cream, Index No. 150173/2024 (N.Y. Sup. Ct. Richmond Cnty.).  Plaintiff alleges the Museum of Ice Cream violated New York Arts & Cultural Affairs law § 25.07(4) ...

Ozempic has been hailed as a miracle drug in recent years. Originally developed by the Danish company Novo Nordisk to help people with type 2 diabetes, it’s since become a popular weight loss drug for off-label use. Ozempic has proved so popular that the brand name has become the catch-all term for many other similar GLP-1 drugs like Wegovy and Mounjaro. Even though an estimated 1 in 8 Americ...

Ozempic has changed the way people think about weight loss. Thanks to semaglutide injections, people have been able to shed excess body mass while also improving their blood sugar levels. It’s estimated that 12% of the American population has taken Ozempic or a similar GLP-1 drug like Wegovy, Mounjaro, or Rybelsus. While Ozempic has many users and vocal proponents, a number of people have dev...

On February 20, 2025, the Honorable Thomas W. Thrash Jr. of the Northern District of Georgia issued an Opinion and Order granting Plaintiff's motion for class certification in the case captioned Jancik v. WebMD LLC, Case No. 1:22-cv-00644 (N.D. Ga.).  Plaintiff alleges WebMD violated the Video Privacy Protection Act ("VPPA") by unlawfully sharing its website users' video viewing activity with u...

On October 11, 2024 Judge Stacey D. Abrams of the United States District Court for the District of New Jersey granted final approval of the class action settlement in George v. Jaguar Land Rover North America LLC.  Bursor & Fisher filed the lawsuit in 2020 alleging that certain Jaguar and Land Rover automobiles were manufactured with unreliable infotainment systems.  The settlement provide...